Literature DB >> 10959781

Pharmacodynamic effects of ketoprofen on crevicular fluid prostanoids in adult periodontitis.

D W Paquette1, H P Lawrence, G B McCombs, R Wilder, T A Binder, E Troullos, M Annett, M Friedman, P C Smith, S Offenbacher.   

Abstract

The reported therapeutic benefits of nonsteroidal anti-inflammatory drugs (NSAIDs) in slowing periodontal disease progression appear intimately linked to the effective inhibition of local prostaglandin synthesis. This randomized, partially double-blind, controlled trial was conducted to evaluate the pharmacodynamic effects of the NSAID, ketoprofen (KTP), on gingival crevicular fluid (GCF) prostanoids. 42 subjects, ages 35-57 years, with moderate to advanced adult periodontitis were recruited and monitored for 22 days. On day 1, subjects were randomized for 1 of 5 treatments: i) 0.5% KTP gel; ii) 1.0% KTP gel; iii) 1.0% KTP alternate gel; iv) 2.0% KTP gel; v) 25 mg KTP capsule (positive control). Subjects applied 1 ml of gel topically to their gingiva or administered one capsule p.o., b.i.d. for 14.5 days. GCF samples were collected from posterior, interproximal sites on days 1 (pre-dosing; 1, 2, 3, 6 h), 8 (pre-dosing; 2 h), 15 (pre-dosing; 2 h) and 22 (post-treatment). GCF levels of prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) were determined using RIA, and expressed in ng/ml and % reduction from baseline (%Effect). Neither a significant difference among groups nor a dose response in % effect for either prostanoid was evident, both overall and among cohorts with elevated baseline mediator levels ([PGE2]>34 ng/ml; [LTB4]>300 ng/ml). When data were combined from all groups, significant (p<0.01) % reductions in GCF PGE2 were noted at 1 and 2 h post-dosing (29% and 24% respectively). In comparing topical versus systemic formulations, all topical formulations were as equipotent as systemic dosing in altering local prostaglandin levels despite lower KTP exposures with gel treatments. These data indicate that both topical and systemic KTP therapies pharmacodynamically reduce GCF PGE2 levels in adult periodontitis subjects, allowing for potential inhibition of disease progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10959781     DOI: 10.1034/j.1600-051x.2000.027008558.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  7 in total

1.  Shifting the paradigm from inhibitors of inflammation to resolvers of inflammation in periodontitis.

Authors:  Thomas E Van Dyke
Journal:  J Periodontol       Date:  2020-06-20       Impact factor: 6.993

2.  Inflammation and uncoupling as mechanisms of periodontal bone loss.

Authors:  D T Graves; J Li; D L Cochran
Journal:  J Dent Res       Date:  2010-12-06       Impact factor: 6.116

3.  Accumulation of topical naproxen by cultured oral epithelium.

Authors:  R R Fitzgerald; J D Walters
Journal:  J Dent Res       Date:  2007-08       Impact factor: 6.116

4.  Design of a multiple drug delivery system directed at periodontitis.

Authors:  Sharath C Sundararaj; Mark V Thomas; Rebecca Peyyala; Thomas D Dziubla; David A Puleo
Journal:  Biomaterials       Date:  2013-08-12       Impact factor: 12.479

5.  The effect of ketoprofen in chronic periodontitis: A clinical double-blind study.

Authors:  M Srinivas; Sangeetha Medaiah; S Girish; M Anil; Jagadish Pai; Amit Walvekar
Journal:  J Indian Soc Periodontol       Date:  2011-07

6.  Efficacy of 2% ibuprofen subgingival irrigation as an adjunct to non-surgical therapy in the treatment of chronic periodontitis: A randomized controlled, split-mouth, clinical trial.

Authors:  Amirhossein Farahmand; Ferena Sayar; Zohreh Omidali; Mahsa Soleimani; Bahareh Jafarzadeh Esfahani
Journal:  J Adv Periodontol Implant Dent       Date:  2019-12-18

7.  The Effects of NF-kB Inhibition with p65-TMD-Linked PTD on Inflammatory Responses at Peri-implantitis Sites.

Authors:  Hyun Jung Jung; Won Lee; Jin-Su Shin; Sang-Kyou Lee; Jae Hoon Lee
Journal:  Inflammation       Date:  2021-06-25       Impact factor: 4.092

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.